Results 171 to 180 of about 70,308 (260)

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis. [PDF]

Sci Rep
Li H, Shi M, Yuan R, Wang H, Li Y.
europepmc   +1 more source

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Analysis of the epidemiological trends of hepatitis A and E in Zhejiang Province and clinical characteristics of severe patients. [PDF]

BMC Infect Dis
Yue X, Gao J, Shao Z, Wu L, Yu J, Miao Z, Pan H.   +6 more
europepmc   +1 more source

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Impact of housing instability on hospital outcomes in alcohol-associated liver disease: A single-center retrospective cohort study. [PDF]

Medicine (Baltimore)
Lee KJ, Fan GH, Huang A, Karagozian R, Almeqdadi M.   +4 more
europepmc   +1 more source

Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature

Australian Veterinary Journal, EarlyView.
Objective To report 45 cases of melioidosis in dogs and cats from northern Australia and analyse trends in epidemiology, clinical presentation, pathogenesis and response to treatment over a 27‐year period. Design Retrospective and prospective analysis of clinical records.
K Lee, C Shilton, S Benedict, M Krockenberger, M Mayo, BJ Currie, R Malik   +6 more
wiley   +1 more source

Dynamic AFP-Defined Disease State Transitions in Hospitalized Patients with Hepatocellular Carcinoma Using the Multi-State Markov Model: A Retrospective Cohort Study. [PDF]

J Hepatocell Carcinoma
Song Q, Zhang H, Jia M, Yu Y, Jiang Y, Yuan J, Su S.   +6 more
europepmc   +1 more source

Real‐world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T‐cell therapy

British Journal of Haematology, EarlyView.
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann‐Haefelin, Gabriel Allo, Philipp Kasper   +11 more
wiley   +1 more source